Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo

International Journal of Cancer

Volumn 118, Issue 12, 2006, Pages 3045-3053

  Renukaradhya, Gourapura J ^a,b   Sriram, Venkataraman ^a,b   Du, Wenjun ^c   Gervay Hague, Jacquelyn ^c   Van Kaer, Luc ^d   Brutkiewicz, Randy R ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTHER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD1D molecules; Cytokines; Invariant NKT cells; RMA S; T cell lymphoma

Indexed keywords

CD1D ANTIGEN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 13; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENETIC TRANSFECTION; IMMUNE RESPONSE; INNATE IMMUNITY; MALE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; TUMOR IMMUNITY;

EID: 33646435567     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21764     Document Type: Article

References (57)

1. Smyth MJ, Godfrey DI. NKT cells and tumor immunity-a double-edged sword. Nat Immunol 2000;1:459-60.
2. Brutkiewicz RR, Sriram V. Natural killer T (NKT) cells and their role in antitumor immunity. Crit Rev Oncol Hematol 2002;41:287-98.
3. Kronenberg M, Gapin L. The unconventional lifestyle of NKT Cells. Nat Rev Immunol 2002;2:557-68.
4. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513.
5. Brutkiewicz RR, Lin Y, Cho S, Hwang YK, Sriram V, Roberts TJ. CD1d-mediated antigen presentation to natural killer T (NKT) cells. Crit Rev Immunol 2003;23:403-19.
6. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells-conductors of tumor immunity? Curr Opin Immunol 2002; 14:165-71.
7. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4-STAT6 pathway. Nat Immunol 2000;1:515-20.
8. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B, Letterio JJ, Paul WE, et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003;198:1741-52.
9. + NKT regulatory cells and IL-13. Int J Cancer 2005; 114:80-7.
10. Chiu YH, Jayawardena J, Weiss A, Lee D, Park SH, Dautry-Varsat A, Bendelac A. Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments. J Exp Med 1999;189:103-10.
11. Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Van Kaer L. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 1997;6:469-77.
12. + T cell compartments. J Immunol 2000;164:739-45.
13. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 1997;278:1623-6.
14. + T-cell antigen receptor a chain in mice. Proc Natl Acad Sci USA 1991;88:7518-22.
15. Sumida T, Sakamoto A, Murata H, Makino Y, Takahashi H, Yoshida S, Nishioka K, Iwamoto I, Taniguchi M. Selective reduction of T cells bearing invariant Vα24JαQ antigen receptor in patients with systemic sclerosis. J Exp Med 1995;182:1163-8.
16. + thymocytes selected by MHC class I molecules. Science 1994;263: 1774-8.
17. + T cells by nonmajor histocompatibility complex-encoded class I-like molecules expressed on bone marrow-derived cells. Proc Natl Acad Sci USA 1995;92:1200-4.
18. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 2003;17:1068-77.
19. Gansuvd B, Hagihara M, Yu Y, Inoue H, Ueda Y, Tsuchiya T, Masui A, Ando K, Nakamura Y, Munkhtuvshin N, Kato S, Thomas JM, et al. Human umbilical cord blood. NK T cells kill tumors by multiple cytotoxic mechanisms. Hum Immunol 2002;63:164-75.
20. + T-cell lymphoma by natural killer T (NKT) cells. Proc Natl Acad Sci USA 2002;99:8197-202.
21. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-8.
22. + T cells produce large amounts of IL-4 and IFN-γ upon activation by anti-CD3 or CD1. J Immunol 1997;159:2240-9.
23. Roberts TJ, Sriram V, Spence PM, Gui M, Hayakawa K, Bacik I, Bennink JR, Yewdell JW, Brutkiewicz RR. Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J Immunol 2002;168:5409-14.
24. Renukaradhya JG, Sriram V, Polakova K, Russ G, Brutkiewicz RR. Development of a quantitative cell-based intracellular ELISA for the screening of B cell hybridoma supernatants: a novel rapid assay to detect positive clones. Hybrid Hybridomics 2004;23:373-9.
25. Brutkiewicz RR, Klaus SJ, Welsh RM. Window of vulnerability of vaccinia virus-infected cells to natural killer (NK) cell-mediated cytolysis correlates with enhanced NK cell triggering and is concomitant with a decrease in H-2 class I antigen expression. Nat Immun 1992;11:203-14.
26. Gunji Y, Vujanovic NL, Hiserodt JC, Herberman RB, Gorelik E. Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J Immunol 1989; 142:1748-54.
27. Du W, Gervay-Hague J. Efficient synthesis of α-galactosyl ceramide analogues using glycosyl iodide donors. Org Lett 2005;7:2063-5.
28. Nahill SR, Welsh RM. High frequency of cross-reactive cytotoxic T lymphocytes elicited during the virus-induced polyclonal cytotoxic T lymphocyte response. J Exp Med 1993;177:317-27.
29. Chang CS, Brossay L, Kronenberg M, Kane KP. The murine non-classical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis. J Exp Med 1999;189:483-91.
30. Bendelac A, Rivera MN, Park SH, Roark JH. Mouse GD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997;15:535-62.
31. - T cells produce IL-4. J Immunol 1992; 149:1211-5.
32. Arase HN, Arase N, Nakagawa K, Good RA, Onoe K. NK1.1+ CD4+ CD8- thymocytes with specific lymphokine secretion. Eur J Immunol 1993;23:307-10.
33. + NK T lymphocytes. J Immunol 1998;161:3271-81.
34. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C, III, Zhou D, Saint-Mezard P, Wang V, Gao Y, Yin N, Hoebe K, Schneewind O, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005;434:525-9.
35. Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, Ho DD, Tsuji M, Kawahara K, Wong CH, Kronenberg M, Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005;434:520-5.
36. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol 2005;35:1692-701.
37. Wu D, Xing GW, Poles MA, Horowitz A, Kinjo Y, Sullivan B, Bodmer-Narkevitch V, Plettenburg O, Kronenberg M, Tsuji M, Ho DD, Wong CH, Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci USA 2005;102:1351-6.
38. Zhou D, Mattner J, Cantu C III, Schrantz N, Yin N, Gao Y, Sagiv Y, Hudspeth K, Wu YP, Yamashita T, Teneberg S, Wang D, et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 2004;306: 1786-9.
39. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002;196:119-27.
40. + T cells and natural killer cells is essential for the anti-metastatic effect of α-galactosylceramide. Blood 2002;99:1259-66.
41. Roberts TJ, Lin Y, Spence PM, Van Kaer L, Brutkiewicz RR. CD1d1-dependent control of the magnitude of an acute antiviral immune response. J Immunol 2004;172:3454-61.
42. Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-γ dependent. J Immunol 2002;169:5796-804.
43. Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ. Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect Immun 2005;73:181-92.
44. Emoto M, Miyamoto M, Emoto Y, Yoshizawa I, Brinkmann V, van Rooijen N, Kaufman SH. Highly biased type I immune responses in mice deficient in LFA-1 in Listeria monocytogenes infection are caused by elevated IL-12 production by granulocytes. J Immunol 2003;171:3970-6.
45. Kawakami K, Kinjo Y, Uezu K, Yara S, Miyagi K, Koguchi Y, Nakayama T, Taniguchi M, Saito A. Monocyte chemoattractant protein-1-dependent increase of Va14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection. J Immunol 2001;167:6525-32.
46. Kawakami K, Yamamoto N, Kinjo Y, Miyagi K, Nakasone C, Uezu K, Kinjo T, Nakayama T, Taniguchi M, Saito A. Critical role of Vα14+ natural killer T cells in the innate phase of host protection against Streptococcus pneumoniae infection. J Immunol 2003;33:3322-30.
47. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, Hong S, Bruna-Romero O, Nakayama T, Nakayama T, Taniguchi M, Bendelac A, Van Kaer L, Koezuka Y, Tsuji M. α-galactosylceramide-activated Va14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA 2000;97:8461-6.
48. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, Nakayama T, Taniguchi M, Koezuka Y, Tsuji M. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002;195:617-24.
49. Schmieg J, Gonzalez-Aseguinolaza G, Tsuji M. The role of natural killer T cells and other T cell subsets against infection by the pre-erythrocytic stages of malaria parasites. Microbes Infect 2003;5:499-506.
50. Schmieg J, Yang G, Frank RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-Galactosylceramide. J Exp Med 2003; 198:1631-41.
51. Dieli F, Taniguchi M, Kronenberg M, Sidobre S, Ivanyi J, Fattorini L, Iona E, Orefici G, De Leo G, Russo D, Caccamo N, Sireci G, et al. An anti-inflammatory role for V a14 NK T cells in Mycobacterium bovis bacillus Calmette-Guerin-infected mice. J Immunol 2003;171: 1961-8.
52. Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J Surg Oncol 1998;68:122-38.
53. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000;60:3239-46.
54. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003;21:624-30.
55. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003;21: 425-56.
56. Hoglund P, Ohlen C, Carbone E, Franksson L, Ljunggren HG, Latour A, Koller B, Karre K. Recognition of β 2-microglobulin-negative (β 2m-) T-cell blasts by natural killer cells from normal but not from β 2m- mice: nonresponsiveness controlled by β 2m- bone marrow in chimeric mice. Proc Natl Acad Sci USA 1991;88:l0332-6.
57. Spence PM, Sriram V, Van Kaer L, Hobbs JA, Brutkiewicz RR. Generation of cellular immunity to lymphocytic choriomeningitis virus is independent of CD1d1 expression. Immunology 2001;104:168-74.